GenSight will participate to EURETINA congress to be held virtually on October 2-4, 2020.

One Free paper will present GS030, our lead gene therapy product candidate, an innovative optogenetic treatment that started a Phase I/II PIONEER clinical trial in Europe and US with patients affected by Retinitis Pigmentosa (RP).

GS030 – Optogenetics in Retinitis Pigmentosa (RP)

  • Title – Optogenetics in the clinic: PIONEER, a phase 1/2a, open-label, non-randomized, dose-escalation study to evaluate safety and tolerability of GS030 in subjects with retinitis pigmentosa
  • Author: Boulanger-Scemama, Fondation Adolphe de Rothschild, Paris, France
  • Program Session: Freepaper
  • Category: New Drug Treatment and Technology